Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

Rhea-AI Summary

Curis (NASDAQ: CRIS) will report fourth quarter 2025 financial and operating results on Thursday, March 19, 2026 at 4:00 p.m. ET.

Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET; dial-in numbers and a live audio webcast will be available via the company website, with a replay posted at www.curis.com.

News Market Reaction – CRIS

-5.93%

5 alerts

-5.93% Session close to close

-3.1% Trough in 2 hr 5 min

$13.05M Market Cap

0.6x Rel. Volume

In the Mar 13 session, CRIS declined 5.93%, reflecting a notable negative market reaction. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.9% in the session following this news. A negative reaction despite this being onl...

Analysis

The stock moved -5.9% in the session following this news. A negative reaction despite this being only an earnings-date notice would fit prior patterns where financings and updates often preceded weakness, such as double-digit declines after the January 2026 PIPE news. The active S-3 for 107,706,700 resale shares may contribute to overhang concerns. With prior filings highlighting losses and liquidity pressure, traders could have treated the approaching Q4 report as a risk event.

Key Figures

Earnings release date: March 19, 2026 Earnings release time: 4:00 p.m. ET Conference call time: 4:30 p.m. ET +2 more

5 metrics

Earnings release date March 19, 2026 Scheduled fourth quarter 2025 results announcement

Earnings release time 4:00 p.m. ET Planned time for Q4 2025 results release

Conference call time 4:30 p.m. ET Start of management call and webcast on results day

US dial-in (800)-836-8184 Domestic participant access number for earnings call

International dial-in (646)-357-8785 International participant access number for earnings call

Historical Context

5 past events · Latest: Jan 09 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 09	Private placement closing	Negative	-2.7%	Closed PIPE financing providing up to $80.8M in gross proceeds.
Jan 07	Private placement pricing	Negative	-16.0%	Priced PIPE with Series B preferred and multiple warrant series.
Dec 09	AML triplet data update	Positive	-1.5%	Reported higher uMRD conversion with stable safety in AML triplet study.
Nov 14	Conference presentation	Positive	+17.7%	Announced multiple emavusertib data presentations at SNO meeting.
Nov 06	Q3 2025 update	Negative	-10.3%	Reported Q3 loss, limited cash, and continued clinical enrollment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Financing and clinical updates have often led to negative or volatile next-day moves, with only one recent event showing a strong positive reaction.

Recent Company History

Over the last few months, Curis has combined clinical progress with significant financing activity. A January 2026 private placement totaling up to $80.8M (news IDs 954234, 955337) drew negative price reactions. Earlier, updated AML triplet data and SNO meeting presentations on emavusertib in late 2025 showed advancing clinical work but produced mixed trading outcomes, including a 17.7% jump on November 14, 2025. The Q3 2025 business update on Nov 6, 2025 highlighted ongoing losses and liquidity constraints, which weighed on the stock. Today’s earnings-date announcement sits against this backdrop of capital-raising and development milestones.

Key Terms

emavusertib, irak4, flt3, nasdaq, +1 more

5 terms

emavusertib medical

"Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948)"

An experimental cancer drug that blocks a specific protein pathway cancer cells use to grow and evade the immune system; think of it as turning down a faulty radio signal that drives tumor survival. It is taken orally and is being tested in clinical trials, so investors watch trial results, safety data, and regulatory progress because successful trials can create a new treatment market and materially affect the maker’s value.

irak4 medical

"an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company"

IRAK4 is a protein in immune-system cells that acts like a control knob for inflammation signals, helping the body detect and respond to infections. Drugs that block IRAK4 can dial down excessive inflammation, so IRAK4 is an important target for developing treatments for autoimmune diseases and some cancers; progress or setbacks in IRAK4 drug programs can materially affect the prospects and valuation of companies working in those areas.

flt3 medical

"an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company"

FLT3 is a gene that makes a protein acting like a growth switch for blood-forming stem cells; when that switch is faulty or overactive it can drive certain blood cancers, most notably acute myeloid leukemia. Investors care because drugs that target FLT3 mutations can become important therapies, influencing clinical trial outcomes, regulatory approvals and the future revenues and valuations of biotech companies—think of it as a key control knob whose position can determine a treatment’s market value.

nasdaq financial

"Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

View in glossary

webcast technical

"Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company has completed its monotherapy and combination studies in acute myeloid leukemia (AML), with additional funding we plan to continue development of emavusertib as a monotherapy and in combination with other agents in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-19-2026-302712824.html

SOURCE Curis, Inc.

FAQ

When will Curis (CRIS) release its fourth quarter 2025 results and hold the conference call?

Curis will release fourth quarter 2025 results on March 19, 2026 at 4:00 p.m. ET. According to the company, management will host a conference call and webcast the same day at 4:30 p.m. ET for investors and analysts.

How can investors join the Curis (CRIS) March 19, 2026 webcast and conference call?

Investors can join by dialing the US number (800)-836-8184 or international (646)-357-8785. According to the company, a live audio webcast will also be accessible from the investor section of the Curis website.

Will a replay be available after the Curis (CRIS) March 19, 2026 conference call?

Yes, a replay of the conference call will be available after the live event. According to the company, the replay will be posted at www.curis.com for later listening by investors and other interested parties.

What topics will Curis (CRIS) likely cover in the March 19, 2026 call about Q4 2025?

The call will cover fourth quarter 2025 financial and operating results and management commentary. According to the company, the webcast and call are intended to provide investors with results, operational updates, and management’s outlook.